ERYTECH reports positive top-line Phase III results from clinical study with GRASPA® in Acute Lymphoblastic Leukemia Post author:admERY Post published:September 30, 2014 Post category:Newsroom ERYTECH reports positive Phase III results from its pivotal study with GRASPA® in Acute Lymphoblastic Leukemia. You Might Also Like ERYTECH wins Deloitte Technology Fast 50 “Promising Biotech Award” for France’s Grand Rhone-Alpes Region November 18, 2015 ERYTECH Pharma to present promising results for the treatment of Sickle Cell Disease March 14, 2011 ERYTECH reports financial highlights for Q1 2015 May 5, 2015
ERYTECH wins Deloitte Technology Fast 50 “Promising Biotech Award” for France’s Grand Rhone-Alpes Region November 18, 2015
